Almirall’s efinaconazole a step closer to European patients

Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole.

The triazole antifungal compound is indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia.

Onychomycosis effects approximately 5.5% of the global population and accounts for 50% of all nail disorder consultations. It is an often persistent and difficult to treat condition with low rates of treatment success due to challenging long-term adherence.